RPRX
Royalty Pharma (RPRX) P/E Ratio
P/E Ratio as of Oct 29, 2026: 35.10
Average32.02
Median31.57
Minimum29.92
Maximum35.10
35.10
4.11 (13.26%)past month
The P/E ratio for Royalty Pharma (RPRX) is 35.10 as of Oct 29, 2026. This represents a increase of 29.71% compared to its 12-month average P/E ratio of 27.06. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Royalty Pharma P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Royalty Pharma’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Royalty Pharma to industry peers.
Royalty Pharma P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Royalty Pharma’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Royalty Pharma to industry peers.
Royalty Pharma (RPRX) P/E Ratio Insights
See Royalty Pharma’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Royalty Pharma (RPRX)
Order type
Buy in
Order amount
Est. shares
0 shares
Royalty Pharma (RPRX) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Oct 1, 2026 | $57.63 | 30.68 |
| Sep 1, 2026 | $62.32 | 33.18 |
| Aug 3, 2026 | $57.17 | 30.43 |
| Jul 1, 2026 | $55.78 | 29.21 |
| Jun 1, 2026 | $55.18 | 28.90 |
| May 1, 2026 | $49.47 | 27.78 |
| Apr 1, 2026 | $48.49 | 27.23 |
| Mar 2, 2026 | $47.47 | 26.66 |
| Feb 2, 2026 | $42.36 | 24.22 |
| Jan 2, 2026 | $38.86 | 22.22 |
Royalty Pharma (RPRX) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | 35.10 | +58.82% |
| 2025 | 22.10 | +121.44% |
| 2024 | 9.98 | -85.78% |
| 2023 | 70.19 | +106.08% |
| 2022 | 34.06 | +29.11% |
| 2021 | 26.38 | — |
FAQs About Royalty Pharma (RPRX) P/E ratio
The latest P/E ratio of Royalty Pharma (RPRX) is 35.10, as of Oct 29, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Royalty Pharma’s last 12-month average P/E ratio is 27.06, compared to its current P/E ratio of 35.10. This reflects a increase of 29.71%.
Royalty Pharma’s current P/E ratio of 35.10 is higher than its last 12-month average P/E of 27.06. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Royalty Pharma’s average P/E ratio over the last 3 years is 21.63. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Royalty Pharma’s average P/E ratio over the last 5 years is 43.1. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.
Royalty Pharma (RPRX) P/E Ratio Insights
See Royalty Pharma’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Royalty Pharma (RPRX)
Order type
Buy in
Order amount
Est. shares
0 shares
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.